Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced new research findings at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD), taking place March 17-21, in Copenhagen and online. Shared in one oral and two poster presentations, the data showcase efforts to advance AD treatment through three key areas which include: developing enhanced brain delivery (EBD™) methods for sabirnetug by developing bispecific antibodies that additionally target Transferrin receptors to improve drug penetration across the blood-brain barrier; evaluating novel biomarker approaches using NULISAseq™ technology to better monitor treatment responses in the central nervous system; and creating highly selective antibodies that specifically target toxic AβOs while avoiding non-toxic monomeric forms of the protein.